PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Under Korea BMI's control, Eyegene is restructuring its pipeline, showing a narrowing operating loss ratio even as repeated capital raises and widening non-operating losses persist.
After Korea BMI became the largest shareholder via a third-party allotment in December 2023, the pipeline was reorganized around a select-and-focus strategy.
2025 revenue rose modestly to the mid-KRW3 billion range and the operating loss ratio improved sharply from 2023, but owners' net loss widened sharply in the fourth quarter of 2025 due to non-operating factors.
The company targets 2027 commercialization centered on near-term revenue candidates, the quadrivalent meningococcal vaccine EG-MCV4 and the recombinant botulinum toxin MBT-002.
Selection for national R&D projects and Phase 1 approval for a COVID-19 mRNA vaccine consortium in 2026 have expanded government-backed research scope.
A history of discontinued or failed pipelines and share dilution from repeated rights offerings remain factors warranting ongoing scrutiny.
Eyegene is a drug developer built on three pillars: mRNA production and delivery technology, a proprietary immune adjuvant system used in premium adult vaccines, and treatments for aging-related ischemic disease.
A technical hallmark is its proprietary cationic liposome delivery platform, EG-R, developed after licensing mRNA technology from US-based TriLink.
After Korea BMI became the largest shareholder via a KRW15 billion third-party share allotment in December 2023, Eyegene reviewed its R&D strategy from scratch and reorganized around candidates with clearer commercial potential.
As a result, the company decided to continue clinical development mainly around the quadrivalent meningococcal vaccine EG-MCV4, licensed from EuBiologics, and the mRNA-based COVID-19 vaccine EG-COVID, while discontinuing further development of other early-stage pipelines.
In May 2025, Eyegene licensed next-generation recombinant botulinum toxin technology, MBT-002 (EG-rBTX100), from Embrix, securing worldwide exclusive development and licensing rights and expanding into the aesthetic medicine field.
Its flagship recombinant protein shingles vaccine, EG-HZ, was licensed domestically to Korea BMI in 2022 under a deal worth roughly KRW21.5 billion including a non-refundable upfront payment of KRW3 billion and milestone payments, with Korea BMI handling subsequent domestic clinical development and commercialization.
As the largest shareholder, Korea BMI has built manufacturing capacity in its Osong, North Chungcheong plant capable of producing about 100 million doses of mRNA vaccine annually in cooperation with Eyegene, providing production and sales synergies.
As of May 2026, Korea BMI held a 23.17% stake as the largest shareholder, with total holdings including special-relationship parties reaching 29.8%.
The company frames EG-MCV4 and MBT-002 as near-term monetization drivers, while positioning the mRNA vaccine platform and an AAV vector gene therapy platform as medium- to long-term growth engines.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩900M | -₩2.5B | −279.6% |
| 2025Q3 | ₩1.1B | -₩1.6B | −150.1% |
| 2025Q4 | ₩800M | -₩3.3B | −420.4% |
| 2026Q1 | ₩1.3B | -₩3.5B | −277.7% |
| 2026Q2 | ₩1.3B | -₩3.9B | −294.8% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩5.3B | -₩24.1B | -₩26.5B | −455.1% | −39.7% | 16.6% |
| 2023 | ₩3.1B | -₩27.1B | -₩22.4B | −866.6% | −35.5% | 21.4% |
| 2024 | ₩3.4B | -₩13.3B | -₩12.1B | −395.0% | −24.1% | 28.5% |
| 2025 | ₩3.6B | -₩9.9B | -₩15.7B | −276.2% | −27.5% | 25.4% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Eyegene's consolidated revenue was KRW3.567 billion in 2025, a slight increase from KRW3.356 billion in 2024, though still below the KRW5.293 billion recorded in 2022. Operating loss narrowed markedly to KRW9.851 billion in 2025 from KRW13.254 billion in 2024 and KRW27.086 billion in 2023.
The operating margin also improved from -866.6% in 2023 to -395.0% in 2024 and -276.2% in 2025. However, net loss attributable to owners widened to KRW15.706 billion in 2025 from KRW12.128 billion in 2024, suggesting that non-operating items drove losses higher even as the operating loss narrowed.
On a quarterly basis, owners' net loss shrank to KRW1.516 billion in the third quarter of 2025 before spiking sharply to KRW8.834 billion in the fourth quarter of 2025, far exceeding that quarter's operating loss of KRW3.254 billion.
Subsequently, in the first and second quarters of 2026, owners' net loss registered KRW3.451 billion and KRW3.751 billion respectively, tracking closer to operating losses of KRW3.533 billion and KRW3.948 billion, without repeating the fourth-quarter divergence.
Combined revenue over the trailing four quarters (Q3 2025 through Q2 2026) totaled approximately KRW4.483 billion, with combined owners' net loss of KRW17.552 billion over the same period.
Operating cash flow improved to negative KRW5.981 billion in 2025 from negative KRW20.065 billion in 2023 and negative KRW18.568 billion in 2022, indicating cost-efficiency efforts are partly reflected in cash flow as well. The debt ratio rose somewhat from 16.6% in 2022 to 25.4% in 2025 but remains at a low level overall.
According to market researcher GIA, the global mRNA vaccine market was estimated to grow from USD64.9 billion in 2021 to USD127.3 billion by 2027.
The shingles vaccine market was projected to grow from USD2.9 billion in 2021 at roughly 10% annually to USD6.0 billion by 2029, a market currently dominated in practice by GSK's FDA-approved recombinant shingles vaccine, Shingrix.
Eyegene is described as the only domestic company to have developed its own mRNA-based vaccine technology, giving it a differentiated position within Korea's mRNA vaccine ecosystem.
In the botulinum toxin market, MBT-002, produced via a genetically recombinant method, is positioned as technically differentiated because it is relatively free from strain-related patent disputes that affect conventional products.
Domestically, government-led R&D support programs—such as the pandemic-preparedness mRNA vaccine development support project run by the Korea National Institute of Health and the Korea Health Industry Development Institute—have expanded, creating opportunities for companies like Eyegene that hold domestic mRNA technology.
That said, a gap remains versus large global pharmaceutical companies in capital strength and clinical development speed, and new pipelines nearing commercialization (EG-MCV4, MBT-002) remain in early development stages that have yet to translate into revenue.
The quadrivalent meningococcal vaccine EG-MCV4 began domestic Phase 2 dosing in mid-October 2025 and completed dosing of all subjects by year-end, with the company targeting completion of Phase 3 trials within 2026 and a planned launch in the domestic public procurement market as well as Southeast Asia and South America starting in 2027.
However, the approval timeline was previously pushed back once when the clinical design was restructured to run Phase 2 and Phase 3 in parallel, warranting continued monitoring of progress.
MBT-002, the botulinum toxin candidate licensed in May 2025, is advancing through non-clinical testing and domestic clinical development, with a goal of entering markets in China, North America, and Europe in addition to Korea.
In August 2026, a consortium of Korea BMI, Eyegene, MicroUni, and Medici Bio received approval for a domestic Phase 1 trial of its COVID-19 mRNA vaccine candidate, BMI2012, targeting a mid-October dosing start.
The consortium is receiving research funding of KRW6.567 billion from the pandemic-preparedness mRNA vaccine development support project run by the Korea National Institute of Health and the Korea Health Industry Development Institute.
In September 2026, Eyegene was selected as a joint research institution for two tasks under the Korea-style ARPA-H project supported by the Ministry of Health and Welfare and the Korea Health Industry Development Institute—a long-lasting immunity vaccine platform targeting highly pathogenic avian influenza, and a platform to eliminate hepatitis B virus reservoirs—securing government funding of KRW13 billion per task, or KRW26 billion in total, over the next five years.
The company has stated that these government projects, combined with collaboration with Korea BMI, are expected to help near-term revenue businesses materialize starting in 2027.
With Eyegene having posted sustained net losses in recent years, a price-to-earnings ratio is difficult to interpret meaningfully, so valuation is more often referenced through the price-to-book ratio. On a self-calculated net asset value basis, the stock trades at a premium to book value rather than at a discount.
Given the ongoing loss structure, no dividends have been paid, making dividend appeal difficult to assess at this stage.
Looking at the multi-year earnings trend, the operating loss ratio has gradually improved since peaking in 2023, but owners' net loss actually widened in 2025 due to non-operating factors, presenting a mixed picture on the quality of earnings improvement.
Since commercialization of new pipelines (EG-MCV4, MBT-002) is scheduled for 2027 or later, current market valuation can be interpreted as reflecting expectations tied substantially to future commercialization outcomes.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
In September 2026, Eyegene was selected for two tasks under the Korea-style ARPA-H project, securing KRW26 billion in government funding over five years. In August of the same year, a COVID-19 mRNA vaccine consortium received Phase 1 approval along with KRW6.567 billion in research funding. Participation in these national projects helps partly offset the company's own R&D cost burden.
In December 2025, Korea BMI over-subscribed to 120% of its allotted rights offering shares, raising its stake from 21.48% to 23.18%. A structure is also in place for sharing the Osong plant's mRNA production facilities and botulinum toxin manufacturing know-how with Eyegene.
The largest shareholder's repeated participation has been cited as a factor supporting investor confidence in accountable management.
Since the 2023 change of largest shareholder, less commercially viable pipelines were pruned and resources concentrated on near-term monetization candidates such as EG-MCV4 and MBT-002. As a result, the operating margin steadily improved from -866.6% in 2023 to -276.2% in 2025. The scale of operating cash outflow also declined significantly in 2025 compared with 2023.
A December 2023 third-party allotment issued new shares equal to 25.8% of total shares outstanding, and a December 2025 rights offering added new shares equal to 59.93% of the prior share count. Repeated large-scale capital raises can weigh on existing shareholders through dilution.
The recurring need for external funding can also be read as reflecting limits on the company's own cash-generation capacity.
The diabetic retinopathy treatment EG-Mirotin had further research discontinued at the Phase 2 stage, and the ischemia-reperfusion injury treatment EG-Myocin failed to demonstrate statistical significance versus placebo in a 2023 Phase 2 trial.
The wound-healing candidate Easydecorin also failed to confirm efficacy in a 2022 Phase 2a trial, and domestic Phase 1/2a trials for the COVID-19 vaccine EG-COVID were discontinued in 2024. The newly restructured pipeline is not immune to similar clinical failure risk.
Owners' net loss in the fourth quarter of 2025 reached KRW8.834 billion, far exceeding that quarter's operating loss of KRW3.254 billion, indicating a significant impact from non-operating factors. Annual revenue still sits in the KRW3-4 billion range, meaning the underlying business scale remains small.
With new pipeline commercialization scheduled for 2027 or later, meaningful revenue-base expansion is unlikely to be expected before then.
EG-MCV4's approval timeline was previously delayed once when its clinical design was restructured to run Phase 2 and Phase 3 in parallel domestically. MBT-002 is also in the transition from non-clinical to domestic clinical stages, so further delays cannot be ruled out.
The COVID-19 mRNA vaccine consortium's Phase 1 trial is likewise at an early stage, and considerable time may be needed before advancing to subsequent trials.
As of end-2025, consolidated equity of KRW54.252 billion included a non-controlling interest of negative KRW2.875 billion, suggesting capital impairment at some consolidated subsidiaries. Operating cash flow has remained persistently negative, leaving the company reliant on external funding. Any further rights offerings or convertible bond issuances could again dilute shareholder value.
The shingles vaccine market is effectively dominated by GSK's Shingrix, creating high entry barriers for later entrants. The botulinum toxin and meningococcal vaccine segments also feature numerous domestic and global competitors, implying intense price and distribution competition at the commercialization stage.
For Eyegene's new pipelines to translate into actual revenue, multiple steps remain, including product approval, securing manufacturing capacity, and building sales networks.
This is the point to check whether the Korea BMI-Eyegene consortium's targeted Phase 1 dosing start for the COVID-19 mRNA vaccine candidate BMI2012 actually occurs.
The third-quarter 2026 quarterly report disclosure should be checked to confirm the continuity of revenue and earnings trends.
Progress toward the company's stated goal of completing EG-MCV4's Phase 3 trial by year-end should be monitored via related disclosures and follow-up schedules.
Interim milestones and funding execution status for the two Korea-style ARPA-H national R&D tasks (a five-year project), agreed in September 2026, should be tracked.
If disclosures emerge on completion of MBT-002's non-clinical studies or filing/approval of a domestic clinical trial application, the specificity of the commercialization roadmap should be reassessed.
Since transitioning to Korea BMI's control at the end of 2023, Eyegene has steadily improved its operating loss ratio by restructuring its pipeline around a select-and-focus strategy.
However, owners' net loss in 2025 actually widened due to non-operating factors, and the sharp fourth-quarter loss spike in particular raises questions about the quality of earnings improvement.
Near-term monetization candidates EG-MCV4 and MBT-002 are progressing toward a targeted 2027 commercialization, while government-backed research scope has also expanded through selection for national R&D projects and entry into a COVID-19 mRNA vaccine consortium's clinical trial.
That said, a history of discontinued or failed pipelines and dilution from repeated large-scale rights offerings remain valid concerns. On the financial side, persistent operating losses and negative cash flow continue alongside a structure heavily reliant on external funding.
Before forming an investment view, it will be important to continue tracking progress on EG-MCV4's Phase 3 trial, the timing of MBT-002's clinical entry, and the volatility of quarterly non-operating gains and losses.
Report written 2026-09-30 · Data as of 2026-09-29
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.